In 2011, the FDA required manufacturers to change a product's labeling to include stronger wording regarding the use of antipsychotics in pregnant women, including consistent information about the potential risk for abnormal muscle movements (extrapyramidal symptoms) and withdrawal symptoms in newborns whose mothers were treated with these drugs during the third trimester of pregnancy. What was the reason for the FDA's requirement?
1) To ensure the safety of pregnant women
2) To inform healthcare professionals about the potential risks
3) To prevent the use of antipsychotics in pregnant women
4) To increase sales of antipsychotic drugs